Dengue Virus Selected Publications

Durbin AP, Whitehead SS.  Next-generation dengue vaccines: novel strategies currently under development. Viruses. 2011 Oct; 3; 10:1800-14.  

Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.  Vaccine. 2011 Sep 23;29(42):7242-50.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wainonek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. A single dose of the DENV-1 candidate vaccine rDEN1?30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. LoS Negl Trop Dis.2011 Aug; 5; 8:e1267

van Panhuis WG, Luxemburger C, Pengsaa K, Limkittkul K, Sabchareon A, Lang J, Durbin AP, Cummings DA. Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg 2011 Aug 85(2): 355-62.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 2011 Jun;7(6):e1002111.

Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemicJ Infect Dis. 2011 Feb 1;203(3):327-34.

Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol . 2010; 338:129-43. Review

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol. 2010;338:145-58. Review. PMID: 19802584

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg. 2009 Nov;81(5):834-41 

 Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg2009 Nov;81(5):834-41 

Durbin AP, Setse R, Omer SB, Palmer JG, Spaeder JA, Baker J, Lessans F, Halsey NA. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine. 2009 Oct 19;27(44):6143-7

McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg. 2008 Nov;79(5):678-84.

Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC. Antigenic relationships between sylvatic and endemic dengue viruses. Am J Trop Med Hyg. 2008 Jul;79(1):128-32.

Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, diamond MS, Pierson TC. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog  2008 May 9 4(5) e000080

Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, Balmaseda A, Harris E. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology. 2008 Jul 5;376(2):429-35. Epub 2008 May 2.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers Vaccine 2008 Feb 13; 26(7):882-90

Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol   2007; 5(7):518-28.

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS.  rDEN2/4Delta30(ME), a live attenuated Chimeric Dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006 Nov-Dec; 2(6):255-60

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.Hum Vaccin. 2006 Jul-Aug; 2(4):167-73.

Blaney JE, Jr., Durbin AP, Murphy BR, Whitehead SS, Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006; 19(1):10-32

Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr., Thumar B, Murphy BR, Karron RA.  rDEN4Delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005 Mar 1; 191:710-8.

Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 2001 Nov;65(5):414-9.

Durbin AP, Karron RA, Thumar B, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a  live attenuated dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in the 3 untranslated region is highly attenuated and immunogenic in humans. Am J Trop Med Hyg  2001 November; 65:405-13.